New Zealand Autism Spectrum Disorder Guideline - Ministry of Health

References
References
298. Wheeler DM, Hazell P, Silove N, et al. Selective
serotonin reuptake inhibitors for the treatment
of autism spectrum disorders (protocol). The
Cochrane Database of Systematic Reviews 2004;
(1).
299. Gordon CT, Rapoport JL, Hamburger SD, et
al. Differential responses of seven subjects
with autistic disorder to clomipramine and
desipramine. American Journal of Psychiatry
1992; 149:363-6.
300. Gordon CT, State RC, Nelson JE. A doubleblind
comparison of clomipramine,
desipramine and placebo in the treatment of
autistic disorder. Archives of General Psychiatry
1993; 50:441-7.
301. Remington G, Sloman L, Konstantareas M, et
al. Clomipramine versus haloperidol in the
treatment of autistic disorder: a double-blind,
placebo-controlled crossover study. Journal of
Clinical Psychopharmacology 2001; 21:440-4.
302. McCracken JT, McGough J, Shah B,
et al. Research Units on Pediatric
Psychopharmacology Autism Network.
Risperidone in children with autism and
serious behavioral problems. New England
Journal of Medicine 2002; 347(5):314-21.
303. Research Units on Pediatric
Psychopharmacology (RUPP) Autism
Network. Risperidone treatment of autistic
disorder: longer-term benefits and blinded
discontinuation after 6 months. American
Journal of Psychiatry 2005; 162(7):1361-9.
304. McDougle CJ, Scahill L, Aman MG, et al.
Risperidone for the core symptom domains of
autism: results from the study by the autism
network of the research unis on pediatric
psychopharmacology. American Journal of
Psychiatry 2005; 162(6):1142-8.
305. Shea S, Turgay A, Carroll A, et al. Risperidone
in the treatment of disruptive behavioral
symptoms in children with autistic and other
pervasive developmental disorders. Paediatrics
2004; 114(5):e634-41.
306. Newcomer J. Second-generation (atypical)
antipsychotics and metabolic effects: a
comprehensive literature review. CNS Drugs
2005; 19(Suppl 1):1-93.
307. Ahl J, Kinon BJ, Liu-Seifert H. Sexual
dysfunction associated with neurolepticinduced
hyperprolactinemia improves with
reduction in prolactin levels. Annals of the New
York Academy of Sciences 2004; 1032:289-90.
308. Yang P, Tsai JH. Occurrence of priapism with
risperidone-paroxetine combination in an
autistic child. Journal of Child and Adolescent
Psychopharmacology 2004; 14(3):342-3.
309. Correll CU, Leucht S, Kane JM. Lower risk for
tardive dyskinesia associated with secondgeneration
antipsychotics: a systematic review
of 1 year studies. American Journal of Psychiatry
2004; 161(3):414-25.
310. Anderson L, Campbell M. The effects of
haloperidol on discrimination learning and
behavioral symptoms in autistic children.
Journal of Autism and Developmental Disorders
1989; 19:227-39.
311. Naruse H, Nagahata M, Nakarey, et al. A
multi-center double-blind trial of pimozide
(orap), haloperidol and placebo in children
with behavioral disorders using a crossover
design. Aeta Paedopsychiatry 1982; 48:1793-84.
312. Campbell M, Armenteros JL, Malone RP, et
al. Neuroleptic-related dyskinesias in autistic
children: a prospective longitudinal study.
Journal of the American Academy of Child and
Adolescent Psychiatry 1997; 36:835-43.
313. Campbell M, Adams PB, Perry R, et al. Tardive
and withdrawal dyskinesia in autistic children.
A prospective study. Psychopharmacology
Bulletin 1988; 24:251-5.
314. Committee on the Safety of Medicines.
Thioridazine: restricted indications and
new warnings on cardiotoxicity. London:
Committee on the Safety of Medicines, 2000.
315. Medsafe. Prescriber Update: Ministry of
Health, 2001.
316. Handen BL, Johnson CR, Lubetsky M. Efficacy
of methylphenidate among children with
autism and symptoms of attention-deficit
hyperactivity disorder. Journal of Autism &
Developmental Disorders 2000; 30:245-55.
317. Quintana H, Birmaher B, Stedge D, et al. Use
of methyphenidate in the treatment of children
with autistic disorder. Journal of Autism &
Developmental Disorders 1995; 25(3):283-94.
318. Research Units on Pediatric
Psychopharmacology (RUPP) Autism Network.
Randomised controlled crossover trial of
methyphenidate in pervasive developmental
disorders with hyperactivity. Archives of General
Psychiatry 2005; 62(11):1266-74.
319. Tordjman S, Anderson GM, Pichard N, et al.
Nocturnal excretion of 6-sulphatoxymelatonin
in children and adolescents with autistic
disorder. Biological Psychiatry 2005; 57(2):134-8.
234
New Zealand Autism Spectrum Disorder Guideline